CA2803697A1 - Beta carboline derivatives useful in the treatment of proliferative disorders - Google Patents

Beta carboline derivatives useful in the treatment of proliferative disorders Download PDF

Info

Publication number
CA2803697A1
CA2803697A1 CA2803697A CA2803697A CA2803697A1 CA 2803697 A1 CA2803697 A1 CA 2803697A1 CA 2803697 A CA2803697 A CA 2803697A CA 2803697 A CA2803697 A CA 2803697A CA 2803697 A1 CA2803697 A1 CA 2803697A1
Authority
CA
Canada
Prior art keywords
halo
hydrogen
hydroxy
optionally substituted
6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2803697A
Other languages
English (en)
French (fr)
Inventor
Raphael Frederick
Bernard Masereel
Jeremy Reniers
Johan Wouters
Celine Bruyere
Robert Kiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Facultes Universitaires Notre Dame de la Paix
Universite Libre de Bruxelles ULB
Original Assignee
Facultes Universitaires Notre Dame de la Paix
Universite Libre de Bruxelles ULB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Facultes Universitaires Notre Dame de la Paix, Universite Libre de Bruxelles ULB filed Critical Facultes Universitaires Notre Dame de la Paix
Publication of CA2803697A1 publication Critical patent/CA2803697A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2803697A 2010-06-25 2011-06-24 Beta carboline derivatives useful in the treatment of proliferative disorders Abandoned CA2803697A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35860910P 2010-06-25 2010-06-25
EP2010059083 2010-06-25
US61/358,609 2010-06-25
EPPCT/EP2010/059083 2010-06-25
PCT/EP2011/060658 WO2011161256A1 (en) 2010-06-25 2011-06-24 Beta carboline derivatives useful in the treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
CA2803697A1 true CA2803697A1 (en) 2011-12-29

Family

ID=44453837

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2803697A Abandoned CA2803697A1 (en) 2010-06-25 2011-06-24 Beta carboline derivatives useful in the treatment of proliferative disorders

Country Status (5)

Country Link
US (1) US9168247B2 (enExample)
EP (1) EP2585463A1 (enExample)
JP (1) JP2013533239A (enExample)
CA (1) CA2803697A1 (enExample)
WO (1) WO2011161256A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968284B1 (en) 2013-03-14 2021-04-21 Osteoqc Inc. Alkyl-amine harmine derivatives for promoting bone growth
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US20160106721A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
CN104530043B (zh) * 2014-12-03 2017-06-06 西北农林科技大学 9‑取代β‑咔啉类化合物及其用于制备预防或治疗肿瘤药物的应用
CN105753860B (zh) * 2014-12-16 2018-03-06 兰州大学 β‑咔啉类生物碱及其在制备抗肿瘤药物中的应用
WO2018119208A1 (en) 2016-12-22 2018-06-28 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
WO2018226998A1 (en) * 2017-06-09 2018-12-13 Global Blood Therapeutics, Inc. Azaindole compounds as histone methyltransferase inhibitors
EP3717475B1 (en) 2017-11-20 2023-06-07 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use
AU2019205944A1 (en) 2018-01-05 2020-07-09 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US11903949B2 (en) 2018-08-14 2024-02-20 Ossifi Therapeutics Llc Fluoro beta-carboline compounds
AU2019321434B2 (en) 2018-08-14 2025-05-08 Ossifi Therapeutics Llc Pyrrolo - dipyridine compounds
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
CN114644626A (zh) * 2020-12-18 2022-06-21 南京施江医药科技有限公司 一种苯环类化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0357122A3 (en) 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19807993A1 (de) * 1998-02-26 1999-09-02 Bayer Ag Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
KR100826817B1 (ko) * 2000-03-15 2008-05-02 사노피-아벤티스 도이칠란트 게엠베하 치환된 베타-카볼린
CN100503607C (zh) * 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
GB0705566D0 (en) * 2007-03-23 2007-05-02 Univ Dundee Method of treating learning impairment in down's syndrome subjects
WO2008157358A1 (en) * 2007-06-15 2008-12-24 University Of Medicine And Dentistry Of New Jersey Methods for treating neoplasia and for identifying compositions useful in such therapy
EP2050747A1 (en) * 2007-10-12 2009-04-22 BioAlliance Pharma Dimers of harmol or of its derivatives and uses thereof
CN101139347B (zh) 2007-10-15 2010-11-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
CN101429198B (zh) 2007-11-09 2013-10-23 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物及其应用
EP2151441A1 (en) * 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤

Also Published As

Publication number Publication date
US20130116273A1 (en) 2013-05-09
WO2011161256A1 (en) 2011-12-29
EP2585463A1 (en) 2013-05-01
US20140005220A9 (en) 2014-01-02
JP2013533239A (ja) 2013-08-22
US9168247B2 (en) 2015-10-27

Similar Documents

Publication Publication Date Title
US9168247B2 (en) Beta carboline derivatives useful in the treatment of proliferative disorders
JP7505023B2 (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
CA2946459C (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
JP6806342B2 (ja) インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ
JP6380862B2 (ja) 複数種類のキナーゼの阻害剤としての縮合三環式アミド系化合物
JP7215687B2 (ja) キナーゼ阻害活性を有する化合物、その製造方法及び用途
WO2019201283A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
JP5872027B2 (ja) ニコチンアミドホスホリボシルトランスフェラーゼ（ｎａｍｐｔ）を阻害するためのピペリジン誘導体および組成物
TWI810803B (zh) 突變蛋白抑制劑的製備及其應用
JP7366996B2 (ja) 抗腫瘍療法で使用するためのデュアルａｔｍ及びｄｎａ－ｐｋ阻害剤
WO2022121813A1 (zh) Sos1抑制剂、包含其的药物组合物及其用途
JP2018519343A (ja) プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
KR20130043198A (ko) 키나제 억제제로서 치환된 이미다조퀴놀린 유도체
JP7557890B2 (ja) 免疫抑制剤、その製造方法及び応用
WO2019037640A1 (en) HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USING THE SAME
KR20140014386A (ko) Ｒａｆ 단백질 키나제를 억제하는 피롤로［２,３-ｂ］피리딘
JP2023518609A (ja) 新規アミノピリミジン系ｅｇｆｒ阻害剤
JP2015508784A (ja) アミド−ベンジルスルホン及びスルホキシド誘導体
CA2819955A1 (en) Substituted imidazoquinoline derivatives
AU2016377678A1 (en) Cortistatin analogs and uses thereof
JP2019534266A (ja) ５員ヘテロアリール環の架橋した環誘導体、その製造方法およびその医学的使用
JP2024540534A (ja) 抗アポトーシスタンパク質ｂｃｌ－２阻害剤、医薬組成物及びその使用
JP2019518032A (ja) Ｐｉ３ｋ ｂｅｔａ阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体
JP2021011492A (ja) ４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン化合物
CA3014581A1 (en) Cortistatin analogs

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170627